United Therapeutics CORP Form 4 insider transactions

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold 22,500 common shares as part of a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 30,375 shares after exercising stock options.

United Therapeutics President and COO Michael Benkowitz exercised options and sold 14,625 shares of common stock as part of a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Director Kevin Tracey received 1,220 restricted stock units as part of his compensation, vesting on January 21, 2027.

A director at United Therapeutics Corporation sold 50 shares of common stock for $460.98 per share under a pre-arranged trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, completed a pre-scheduled exercise of stock options and subsequent sale of common stock.

United Therapeutics President and COO Michael Benkowitz executed a pre-arranged sale of 14,625 common shares following the exercise of stock options, as disclosed in a recent SEC Form 4 filing.

United Therapeutics President and COO Michael Benkowitz exercised stock options and sold the resulting shares totaling 7,875, pursuant to a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Causey exercised stock options and subsequently sold 1,000 shares of common stock for $510 per share under a pre-arranged 10b5-1 plan.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $495.01 per share under a pre-arranged 10b5-1 trading plan.

Christopher Causey, a director at United Therapeutics Corp, exercised stock options and subsequently sold 1,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 8,300 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold the resulting shares totaling 22,500 under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned option exercises and subsequent sales of company common stock totaling 22,500 shares.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $512.12 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Louis W. Sullivan exercised stock options and subsequently sold all beneficially owned common stock through a trust on December 22, 2025.

United Therapeutics Director Tommy G Thompson exercised stock options and subsequently sold an equal number of common shares on December 18, 2025.

United Therapeutics CEO Martine Rothblatt completed the final transactions under a pre-arranged 10b5-1 trading plan, exercising options and selling common stock.

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, CEO of United Therapeutics, executed planned stock option exercises and subsequent sales of common stock totaling 8,000 shares.

United Therapeutics' President and COO, Michael Benkowitz, executed a pre-planned sale of common stock following the exercise of stock options.

United Therapeutics Director Christopher Patusky exercised stock options and sold 1,000 shares of common stock in a pre-planned transaction.

United Therapeutics Director Jan Malcolm sold 50 shares of common stock for $482.98 per share under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 11,000 shares of common stock for approximately $5.3 million under a pre-arranged 10b5-1 plan.

United Therapeutics Corp. CEO Martine A. Rothblatt exercised and sold common stock options totaling 8,000 shares over two days in December 2025, pursuant to a pre-arranged trading plan.

United Therapeutics Corp. Director Nilda Mesa reported the sale of 187 common shares under a pre-arranged trading plan.

United Therapeutics CEO Martine Rothblatt reported the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics' CFO and Treasurer, James Edgemond, exercised stock options and subsequently sold a significant portion of the acquired shares under a pre-arranged 10b5-1 trading plan.